Fernando Holguin
Concepts (613)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 126 | 2025 | 2295 | 12.550 |
Why?
| | Obesity | 34 | 2024 | 2992 | 3.480 |
Why?
| | Air Pollutants | 19 | 2025 | 430 | 2.640 |
Why?
| | Anti-Asthmatic Agents | 14 | 2025 | 395 | 2.350 |
Why?
| | Vehicle Emissions | 11 | 2017 | 67 | 2.240 |
Why?
| | Citrulline | 3 | 2023 | 45 | 1.920 |
Why?
| | Nitric Oxide | 17 | 2025 | 915 | 1.910 |
Why?
| | Lung | 26 | 2025 | 4060 | 1.600 |
Why?
| | Air Pollution | 12 | 2024 | 316 | 1.400 |
Why?
| | Environmental Exposure | 15 | 2025 | 579 | 1.340 |
Why?
| | Minority Groups | 3 | 2021 | 266 | 1.330 |
Why?
| | Arginine | 5 | 2023 | 271 | 1.310 |
Why?
| | Adrenal Cortex Hormones | 20 | 2025 | 565 | 1.310 |
Why?
| | Metabolic Syndrome | 4 | 2019 | 354 | 1.240 |
Why?
| | Lung Diseases | 5 | 2021 | 767 | 1.210 |
Why?
| | Humans | 159 | 2025 | 137585 | 1.100 |
Why?
| | September 11 Terrorist Attacks | 2 | 2021 | 32 | 1.090 |
Why?
| | Bronchial Hyperreactivity | 4 | 2025 | 111 | 1.070 |
Why?
| | Patient Selection | 2 | 2021 | 696 | 1.070 |
Why?
| | Particulate Matter | 12 | 2025 | 315 | 1.050 |
Why?
| | Dietary Supplements | 5 | 2019 | 561 | 1.000 |
Why?
| | Hospitalization | 8 | 2020 | 2199 | 0.970 |
Why?
| | Inflammation | 14 | 2020 | 2837 | 0.950 |
Why?
| | Forced Expiratory Volume | 16 | 2021 | 531 | 0.950 |
Why?
| | Respiratory Sounds | 3 | 2021 | 125 | 0.940 |
Why?
| | Oxidative Stress | 9 | 2024 | 1317 | 0.940 |
Why?
| | Adult | 73 | 2024 | 37929 | 0.910 |
Why?
| | Plant Stems | 1 | 2024 | 7 | 0.880 |
Why?
| | Severity of Illness Index | 22 | 2021 | 2828 | 0.870 |
Why?
| | Tocopherols | 1 | 2024 | 26 | 0.870 |
Why?
| | Asteraceae | 1 | 2024 | 18 | 0.860 |
Why?
| | Pulmonary Medicine | 3 | 2021 | 85 | 0.860 |
Why?
| | Bronchodilator Agents | 9 | 2023 | 252 | 0.850 |
Why?
| | Glucocorticoids | 5 | 2024 | 594 | 0.840 |
Why?
| | Mucus | 4 | 2025 | 79 | 0.820 |
Why?
| | Respiratory Function Tests | 11 | 2020 | 600 | 0.800 |
Why?
| | Nitrogen Dioxide | 5 | 2025 | 47 | 0.800 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 134 | 0.800 |
Why?
| | Plant Leaves | 1 | 2024 | 147 | 0.780 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 18 | 0.760 |
Why?
| | Fatty Acids, Omega-3 | 4 | 2015 | 140 | 0.740 |
Why?
| | Middle Aged | 56 | 2024 | 33479 | 0.740 |
Why?
| | Microalgae | 2 | 2018 | 10 | 0.740 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 11 | 0.730 |
Why?
| | Phenotype | 16 | 2025 | 3196 | 0.730 |
Why?
| | Gonadal Steroid Hormones | 2 | 2020 | 140 | 0.720 |
Why?
| | Thiazolidinediones | 2 | 2015 | 137 | 0.720 |
Why?
| | Male | 86 | 2025 | 67762 | 0.720 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 293 | 0.700 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 6 | 2022 | 1040 | 0.700 |
Why?
| | Female | 85 | 2025 | 73304 | 0.690 |
Why?
| | Transients and Migrants | 2 | 2018 | 24 | 0.670 |
Why?
| | Fluticasone | 5 | 2021 | 90 | 0.670 |
Why?
| | Respiratory Mucosa | 7 | 2025 | 321 | 0.660 |
Why?
| | Heart Rate | 3 | 2013 | 822 | 0.650 |
Why?
| | Hydroxyurea | 1 | 2019 | 35 | 0.650 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2019 | 37 | 0.650 |
Why?
| | Respiratory Tract Diseases | 3 | 2017 | 184 | 0.630 |
Why?
| | Administration, Inhalation | 15 | 2024 | 688 | 0.630 |
Why?
| | Social Class | 2 | 2021 | 282 | 0.620 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2019 | 11 | 0.620 |
Why?
| | Leptin | 3 | 2011 | 236 | 0.620 |
Why?
| | Immunoglobulin E | 7 | 2025 | 342 | 0.610 |
Why?
| | Carotenoids | 1 | 2019 | 43 | 0.610 |
Why?
| | Stramenopiles | 1 | 2018 | 1 | 0.610 |
Why?
| | Adiponectin | 3 | 2011 | 244 | 0.600 |
Why?
| | Biosynthetic Pathways | 1 | 2018 | 24 | 0.600 |
Why?
| | Risk Factors | 23 | 2025 | 10388 | 0.600 |
Why?
| | Young Adult | 27 | 2021 | 13209 | 0.590 |
Why?
| | Age of Onset | 5 | 2018 | 518 | 0.590 |
Why?
| | Pulmonary Eosinophilia | 1 | 2018 | 27 | 0.590 |
Why?
| | Biological Products | 1 | 2021 | 216 | 0.580 |
Why?
| | Body Mass Index | 13 | 2024 | 2389 | 0.580 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1477 | 0.560 |
Why?
| | Bronchoalveolar Lavage Fluid | 10 | 2020 | 652 | 0.560 |
Why?
| | Biomedical Research | 2 | 2021 | 692 | 0.550 |
Why?
| | Pyridones | 1 | 2019 | 168 | 0.550 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 110 | 0.540 |
Why?
| | Thinness | 3 | 2021 | 91 | 0.530 |
Why?
| | Critical Care | 2 | 2021 | 601 | 0.530 |
Why?
| | Acclimatization | 1 | 2018 | 177 | 0.530 |
Why?
| | Nitrosative Stress | 1 | 2016 | 4 | 0.530 |
Why?
| | Fluorocarbons | 1 | 2018 | 117 | 0.520 |
Why?
| | Biomarkers | 15 | 2025 | 4149 | 0.510 |
Why?
| | Respiratory Tract Infections | 4 | 2016 | 390 | 0.500 |
Why?
| | Salmeterol Xinafoate | 3 | 2021 | 41 | 0.500 |
Why?
| | Triglycerides | 1 | 2018 | 524 | 0.500 |
Why?
| | Dyslipidemias | 1 | 2017 | 176 | 0.490 |
Why?
| | Adolescent | 35 | 2025 | 21513 | 0.480 |
Why?
| | Soybean Oil | 2 | 2005 | 14 | 0.480 |
Why?
| | Fish Oils | 2 | 2005 | 26 | 0.480 |
Why?
| | Ozone | 4 | 2025 | 132 | 0.470 |
Why?
| | Environmental Monitoring | 6 | 2017 | 370 | 0.470 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 329 | 0.460 |
Why?
| | Oxidation-Reduction | 4 | 2018 | 1060 | 0.460 |
Why?
| | Fatty Acids, Omega-6 | 2 | 2015 | 48 | 0.450 |
Why?
| | United States | 24 | 2023 | 14841 | 0.430 |
Why?
| | Inflammation Mediators | 3 | 2014 | 513 | 0.430 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 660 | 0.430 |
Why?
| | Insect Repellents | 2 | 2024 | 6 | 0.430 |
Why?
| | Exhalation | 2 | 2020 | 39 | 0.430 |
Why?
| | Epithelial Cells | 7 | 2023 | 1096 | 0.420 |
Why?
| | Carbon Monoxide | 1 | 2013 | 81 | 0.410 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3284 | 0.410 |
Why?
| | Child | 35 | 2025 | 21935 | 0.410 |
Why?
| | Eczema | 1 | 2014 | 69 | 0.410 |
Why?
| | Aged | 23 | 2024 | 23961 | 0.410 |
Why?
| | Ornithine | 2 | 2023 | 26 | 0.400 |
Why?
| | Eosinophils | 6 | 2025 | 332 | 0.400 |
Why?
| | Health Status | 2 | 2024 | 792 | 0.400 |
Why?
| | Morbidity | 3 | 2023 | 324 | 0.400 |
Why?
| | Inhalation Exposure | 1 | 2013 | 105 | 0.400 |
Why?
| | Hospital Mortality | 3 | 2020 | 911 | 0.390 |
Why?
| | Rhinitis | 1 | 2014 | 158 | 0.380 |
Why?
| | Lung Diseases, Obstructive | 1 | 2012 | 50 | 0.370 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 285 | 0.370 |
Why?
| | Immunologic Factors | 1 | 2014 | 236 | 0.370 |
Why?
| | Air Pollutants, Occupational | 1 | 2012 | 40 | 0.370 |
Why?
| | Dust | 1 | 2012 | 100 | 0.360 |
Why?
| | Firefighters | 1 | 2012 | 43 | 0.360 |
Why?
| | Prevalence | 7 | 2020 | 2734 | 0.350 |
Why?
| | Double-Blind Method | 11 | 2019 | 1993 | 0.350 |
Why?
| | Bronchoconstriction | 2 | 2010 | 32 | 0.340 |
Why?
| | Comorbidity | 10 | 2023 | 1622 | 0.340 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2111 | 0.340 |
Why?
| | Quality of Life | 8 | 2023 | 2892 | 0.330 |
Why?
| | Pediatric Obesity | 1 | 2017 | 601 | 0.330 |
Why?
| | Eosinophilia | 3 | 2020 | 218 | 0.330 |
Why?
| | Airway Resistance | 1 | 2010 | 41 | 0.320 |
Why?
| | Sputum | 6 | 2019 | 311 | 0.320 |
Why?
| | Hypersensitivity | 3 | 2022 | 257 | 0.320 |
Why?
| | Atherosclerosis | 1 | 2014 | 415 | 0.320 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 67 | 0.320 |
Why?
| | Alendronate | 2 | 2019 | 15 | 0.310 |
Why?
| | Intensive Care Units | 2 | 2020 | 827 | 0.310 |
Why?
| | Overweight | 3 | 2024 | 558 | 0.310 |
Why?
| | Air Pollution, Indoor | 3 | 2024 | 180 | 0.310 |
Why?
| | Pneumocystis carinii | 1 | 2009 | 12 | 0.310 |
Why?
| | Spirometry | 4 | 2023 | 281 | 0.310 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2009 | 38 | 0.300 |
Why?
| | Heart Ventricles | 1 | 2014 | 788 | 0.300 |
Why?
| | Hydrogen Peroxide | 3 | 2022 | 328 | 0.300 |
Why?
| | Child, Preschool | 17 | 2025 | 11074 | 0.300 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 36 | 0.300 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 1114 | 0.300 |
Why?
| | Health Services | 1 | 2009 | 107 | 0.290 |
Why?
| | Precision Medicine | 3 | 2021 | 429 | 0.290 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 257 | 0.290 |
Why?
| | Health Services Accessibility | 3 | 2024 | 986 | 0.290 |
Why?
| | Mexico | 7 | 2013 | 225 | 0.290 |
Why?
| | Vasculitis | 1 | 2008 | 66 | 0.290 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 127 | 0.290 |
Why?
| | Occupational Exposure | 1 | 2012 | 341 | 0.280 |
Why?
| | Mucins | 2 | 2025 | 73 | 0.280 |
Why?
| | Th2 Cells | 3 | 2019 | 176 | 0.270 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1509 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 804 | 0.270 |
Why?
| | Isoprostanes | 1 | 2007 | 15 | 0.270 |
Why?
| | Bronchi | 3 | 2018 | 260 | 0.270 |
Why?
| | Aged, 80 and over | 7 | 2020 | 7635 | 0.270 |
Why?
| | Treatment Outcome | 10 | 2025 | 10811 | 0.270 |
Why?
| | Breath Tests | 4 | 2018 | 87 | 0.270 |
Why?
| | Fatty Acids | 2 | 2021 | 443 | 0.270 |
Why?
| | Schools | 6 | 2021 | 461 | 0.270 |
Why?
| | Albuterol | 5 | 2023 | 110 | 0.260 |
Why?
| | Patient Admission | 1 | 2008 | 197 | 0.260 |
Why?
| | Refugees | 2 | 2018 | 75 | 0.260 |
Why?
| | Disease Progression | 9 | 2025 | 2757 | 0.260 |
Why?
| | Cytokines | 5 | 2019 | 2085 | 0.260 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5472 | 0.250 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2607 | 0.250 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2844 | 0.240 |
Why?
| | Aedes | 2 | 2024 | 65 | 0.240 |
Why?
| | Interleukin-13 | 4 | 2020 | 149 | 0.240 |
Why?
| | Logistic Models | 4 | 2020 | 2074 | 0.240 |
Why?
| | Chlamydomonas reinhardtii | 2 | 2015 | 8 | 0.240 |
Why?
| | Societies, Medical | 5 | 2023 | 820 | 0.230 |
Why?
| | Fucosyltransferases | 1 | 2025 | 33 | 0.230 |
Why?
| | Cholecalciferol | 2 | 2016 | 60 | 0.230 |
Why?
| | Self Report | 2 | 2019 | 827 | 0.230 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 75 | 0.230 |
Why?
| | Leukocyte Count | 4 | 2020 | 329 | 0.220 |
Why?
| | Resins, Plant | 1 | 2024 | 5 | 0.220 |
Why?
| | Rubber | 1 | 2024 | 7 | 0.220 |
Why?
| | Sex Factors | 4 | 2018 | 2071 | 0.220 |
Why?
| | Prospective Studies | 9 | 2024 | 7604 | 0.220 |
Why?
| | Nitrogen | 2 | 2015 | 168 | 0.210 |
Why?
| | Respiration, Artificial | 3 | 2020 | 645 | 0.210 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.210 |
Why?
| | Mexican Americans | 1 | 2004 | 120 | 0.210 |
Why?
| | Lipid Metabolism | 2 | 2018 | 518 | 0.210 |
Why?
| | Microbiota | 3 | 2022 | 762 | 0.200 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 91 | 0.200 |
Why?
| | Oils, Volatile | 1 | 2023 | 6 | 0.200 |
Why?
| | Insect Bites and Stings | 1 | 2023 | 12 | 0.200 |
Why?
| | Ixodes | 1 | 2023 | 14 | 0.200 |
Why?
| | Arabidopsis | 1 | 2024 | 95 | 0.200 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 186 | 0.200 |
Why?
| | Vital Capacity | 4 | 2021 | 311 | 0.200 |
Why?
| | Proof of Concept Study | 2 | 2019 | 78 | 0.200 |
Why?
| | Respiratory System | 3 | 2020 | 157 | 0.200 |
Why?
| | Reflex | 1 | 2023 | 68 | 0.200 |
Why?
| | Housing | 1 | 2024 | 146 | 0.200 |
Why?
| | Vagus Nerve | 1 | 2023 | 86 | 0.190 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2019 | 173 | 0.190 |
Why?
| | Pilot Projects | 2 | 2019 | 1710 | 0.190 |
Why?
| | Nutrition Surveys | 3 | 2018 | 266 | 0.190 |
Why?
| | Incidence | 5 | 2020 | 2804 | 0.190 |
Why?
| | Quercetin | 1 | 2022 | 15 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 135 | 0.190 |
Why?
| | Hypersensitivity, Immediate | 2 | 2016 | 44 | 0.190 |
Why?
| | Nitro Compounds | 1 | 2021 | 6 | 0.180 |
Why?
| | Antioxidants | 4 | 2016 | 584 | 0.180 |
Why?
| | Oleic Acids | 1 | 2021 | 11 | 0.180 |
Why?
| | Geography | 2 | 2021 | 200 | 0.180 |
Why?
| | Smoking | 3 | 2020 | 1627 | 0.180 |
Why?
| | Residence Characteristics | 1 | 2004 | 351 | 0.180 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 318 | 0.180 |
Why?
| | Omalizumab | 1 | 2021 | 51 | 0.180 |
Why?
| | Waiting Lists | 1 | 2023 | 266 | 0.180 |
Why?
| | Life Style | 2 | 2023 | 490 | 0.180 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 64 | 0.180 |
Why?
| | Arginase | 1 | 2021 | 32 | 0.180 |
Why?
| | Signal Transduction | 5 | 2020 | 5079 | 0.180 |
Why?
| | Automobiles | 3 | 2011 | 19 | 0.170 |
Why?
| | Public Policy | 1 | 2021 | 85 | 0.170 |
Why?
| | Symptom Flare Up | 1 | 2020 | 39 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2018 | 99 | 0.170 |
Why?
| | Patient Advocacy | 1 | 2021 | 76 | 0.170 |
Why?
| | Self-Management | 1 | 2023 | 176 | 0.170 |
Why?
| | Public Health | 3 | 2018 | 588 | 0.170 |
Why?
| | Stakeholder Participation | 1 | 2021 | 78 | 0.170 |
Why?
| | Geographic Mapping | 1 | 2020 | 24 | 0.170 |
Why?
| | Disulfides | 1 | 2021 | 107 | 0.170 |
Why?
| | Health Policy | 2 | 2021 | 388 | 0.170 |
Why?
| | Lung Transplantation | 1 | 2023 | 313 | 0.170 |
Why?
| | Geographic Information Systems | 1 | 2020 | 45 | 0.170 |
Why?
| | Socioeconomic Factors | 4 | 2018 | 1289 | 0.170 |
Why?
| | Mucin 5AC | 3 | 2025 | 70 | 0.170 |
Why?
| | Frailty | 1 | 2023 | 170 | 0.170 |
Why?
| | Case-Control Studies | 6 | 2020 | 3556 | 0.160 |
Why?
| | Trust | 1 | 2021 | 127 | 0.160 |
Why?
| | Chemotaxis | 1 | 2020 | 131 | 0.160 |
Why?
| | Soot | 3 | 2015 | 26 | 0.160 |
Why?
| | Neutrophils | 3 | 2020 | 1238 | 0.160 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 200 | 0.160 |
Why?
| | Puberty | 2 | 2018 | 146 | 0.160 |
Why?
| | Muscarinic Antagonists | 1 | 2019 | 29 | 0.160 |
Why?
| | Poverty | 1 | 2024 | 521 | 0.160 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 51 | 0.160 |
Why?
| | Dyspnea | 1 | 2022 | 254 | 0.160 |
Why?
| | Uncertainty | 1 | 2020 | 128 | 0.160 |
Why?
| | Diet | 2 | 2019 | 1278 | 0.160 |
Why?
| | Age Factors | 5 | 2018 | 3295 | 0.160 |
Why?
| | Th1 Cells | 2 | 2017 | 143 | 0.160 |
Why?
| | Gene Expression | 4 | 2018 | 1502 | 0.160 |
Why?
| | Nitric Oxide Synthase | 2 | 2019 | 240 | 0.160 |
Why?
| | Mometasone Furoate | 1 | 2019 | 5 | 0.160 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 37 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 321 | 0.160 |
Why?
| | Mucin-4 | 1 | 2019 | 4 | 0.160 |
Why?
| | Sialyltransferases | 1 | 2019 | 13 | 0.160 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 19 | 0.150 |
Why?
| | 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2018 | 7 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 45 | 0.150 |
Why?
| | Saline Waters | 1 | 2018 | 1 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2021 | 234 | 0.150 |
Why?
| | Dioxanes | 1 | 2018 | 10 | 0.150 |
Why?
| | Immunity | 2 | 2022 | 143 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2526 | 0.150 |
Why?
| | Interleukins | 1 | 2020 | 250 | 0.150 |
Why?
| | Cities | 4 | 2013 | 133 | 0.150 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 200 | 0.150 |
Why?
| | Immunoglobulin Fragments | 1 | 2018 | 12 | 0.150 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 175 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1483 | 0.150 |
Why?
| | Exercise Test | 1 | 2022 | 625 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.150 |
Why?
| | Moraxella | 1 | 2018 | 5 | 0.150 |
Why?
| | Airway Remodeling | 2 | 2016 | 64 | 0.150 |
Why?
| | Porosity | 1 | 2018 | 102 | 0.150 |
Why?
| | Cross-Over Studies | 4 | 2025 | 564 | 0.150 |
Why?
| | DNA Methylation | 1 | 2023 | 643 | 0.140 |
Why?
| | Adsorption | 1 | 2018 | 149 | 0.140 |
Why?
| | Weight Loss | 2 | 2023 | 787 | 0.140 |
Why?
| | Water | 2 | 2018 | 460 | 0.140 |
Why?
| | Metabolome | 2 | 2018 | 350 | 0.140 |
Why?
| | Emergency Service, Hospital | 2 | 2025 | 2069 | 0.140 |
Why?
| | Corynebacterium | 1 | 2018 | 49 | 0.140 |
Why?
| | Silicon Dioxide | 1 | 2018 | 115 | 0.140 |
Why?
| | Retrospective Studies | 8 | 2023 | 15657 | 0.140 |
Why?
| | Cold Temperature | 1 | 2018 | 179 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1266 | 0.130 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2021 | 22 | 0.130 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 5778 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 638 | 0.130 |
Why?
| | Quinolones | 1 | 2018 | 137 | 0.130 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 10 | 0.130 |
Why?
| | Volatile Organic Compounds | 1 | 2017 | 61 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 273 | 0.130 |
Why?
| | Voice Quality | 1 | 2016 | 22 | 0.130 |
Why?
| | Leukotriene Antagonists | 1 | 2016 | 43 | 0.130 |
Why?
| | Water Purification | 1 | 2018 | 152 | 0.130 |
Why?
| | Aminophenols | 1 | 2018 | 156 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2020 | 2833 | 0.130 |
Why?
| | Functional Food | 1 | 2016 | 2 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 341 | 0.130 |
Why?
| | Food Quality | 1 | 2016 | 10 | 0.130 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 88 | 0.130 |
Why?
| | Chemokines, CC | 2 | 2014 | 33 | 0.130 |
Why?
| | Pigments, Biological | 1 | 2016 | 16 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 169 | 0.130 |
Why?
| | Vitamins | 2 | 2015 | 185 | 0.130 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2015 | 14 | 0.120 |
Why?
| | Crops, Agricultural | 1 | 2016 | 30 | 0.120 |
Why?
| | Bronchoconstrictor Agents | 1 | 2015 | 16 | 0.120 |
Why?
| | Zea mays | 1 | 2016 | 41 | 0.120 |
Why?
| | Vermont | 1 | 2015 | 9 | 0.120 |
Why?
| | Income | 1 | 2017 | 202 | 0.120 |
Why?
| | Ibuprofen | 1 | 2016 | 84 | 0.120 |
Why?
| | Antigens, CD | 1 | 2019 | 521 | 0.120 |
Why?
| | Methacholine Chloride | 1 | 2015 | 52 | 0.120 |
Why?
| | Anthocyanins | 1 | 2016 | 33 | 0.120 |
Why?
| | Bronchial Provocation Tests | 1 | 2015 | 51 | 0.120 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 6 | 0.120 |
Why?
| | Preventive Medicine | 1 | 2016 | 42 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2019 | 217 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.120 |
Why?
| | Seeds | 1 | 2016 | 86 | 0.120 |
Why?
| | Health Surveys | 2 | 2009 | 514 | 0.120 |
Why?
| | Blood Platelets | 1 | 2019 | 408 | 0.120 |
Why?
| | Homocysteine | 1 | 2015 | 156 | 0.120 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2015 | 3 | 0.120 |
Why?
| | Healthcare Disparities | 2 | 2023 | 654 | 0.120 |
Why?
| | Transportation | 1 | 2015 | 53 | 0.120 |
Why?
| | Azithromycin | 1 | 2015 | 100 | 0.110 |
Why?
| | Mice | 8 | 2025 | 17787 | 0.110 |
Why?
| | Fibrinogen | 1 | 2015 | 168 | 0.110 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 131 | 0.110 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2691 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 985 | 0.110 |
Why?
| | Pennsylvania | 4 | 2016 | 116 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 233 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 900 | 0.110 |
Why?
| | Pregnenediones | 1 | 2014 | 19 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2017 | 289 | 0.110 |
Why?
| | Photosynthesis | 1 | 2014 | 104 | 0.110 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2016 | 165 | 0.110 |
Why?
| | Interleukin-6 | 2 | 2016 | 778 | 0.110 |
Why?
| | Acetaminophen | 1 | 2016 | 268 | 0.100 |
Why?
| | Cohort Studies | 8 | 2020 | 5742 | 0.100 |
Why?
| | Lipids | 2 | 2015 | 672 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 410 | 0.100 |
Why?
| | Cells, Cultured | 5 | 2020 | 4193 | 0.100 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 286 | 0.100 |
Why?
| | Receptors, Prostaglandin | 1 | 2013 | 22 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 23 | 0.100 |
Why?
| | Linear Models | 4 | 2018 | 849 | 0.100 |
Why?
| | Nutritional Status | 1 | 2015 | 350 | 0.100 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5757 | 0.100 |
Why?
| | Odds Ratio | 1 | 2015 | 1070 | 0.100 |
Why?
| | Metallurgy | 1 | 2012 | 8 | 0.100 |
Why?
| | Chemokine CCL24 | 1 | 2012 | 12 | 0.100 |
Why?
| | Dinoprost | 2 | 2009 | 44 | 0.100 |
Why?
| | Gene Regulatory Networks | 1 | 2015 | 305 | 0.100 |
Why?
| | Texas | 4 | 2017 | 244 | 0.100 |
Why?
| | Time Factors | 2 | 2015 | 6828 | 0.100 |
Why?
| | Brazil | 2 | 2023 | 167 | 0.100 |
Why?
| | Macrophages, Alveolar | 3 | 2015 | 391 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.100 |
Why?
| | Mucin-5B | 2 | 2025 | 224 | 0.090 |
Why?
| | Particle Size | 3 | 2011 | 394 | 0.090 |
Why?
| | Weight Gain | 1 | 2015 | 519 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1272 | 0.090 |
Why?
| | Interferon-gamma | 1 | 2015 | 789 | 0.090 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 216 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1774 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 2057 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1991 | 0.090 |
Why?
| | Leukotriene E4 | 1 | 2011 | 27 | 0.090 |
Why?
| | Mental Health | 1 | 2017 | 726 | 0.080 |
Why?
| | Glutathione Transferase | 2 | 2009 | 106 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1139 | 0.080 |
Why?
| | Functional Residual Capacity | 1 | 2010 | 8 | 0.080 |
Why?
| | Inhalation | 1 | 2010 | 29 | 0.080 |
Why?
| | Alabama | 1 | 2009 | 33 | 0.080 |
Why?
| | Nitrites | 1 | 2009 | 84 | 0.080 |
Why?
| | Illinois | 1 | 2009 | 43 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 49 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2025 | 3015 | 0.080 |
Why?
| | Nitrates | 1 | 2009 | 92 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2017 | 1208 | 0.080 |
Why?
| | Tyrosine | 1 | 2009 | 222 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2008 | 24 | 0.080 |
Why?
| | Gases | 1 | 2009 | 48 | 0.070 |
Why?
| | Chlorine | 1 | 2009 | 61 | 0.070 |
Why?
| | Depression | 2 | 2016 | 1397 | 0.070 |
Why?
| | California | 1 | 2009 | 431 | 0.070 |
Why?
| | Mice, Obese | 1 | 2007 | 66 | 0.070 |
Why?
| | Medication Adherence | 2 | 2023 | 467 | 0.070 |
Why?
| | Pneumonia | 2 | 2020 | 639 | 0.070 |
Why?
| | Mutation | 1 | 2018 | 3958 | 0.070 |
Why?
| | Employer Health Costs | 1 | 2006 | 2 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2009 | 565 | 0.070 |
Why?
| | Glutathione | 1 | 2009 | 356 | 0.070 |
Why?
| | Anti-Retroviral Agents | 1 | 2009 | 233 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3566 | 0.070 |
Why?
| | PPAR gamma | 1 | 2007 | 182 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2021 | 271 | 0.060 |
Why?
| | Phagocytosis | 1 | 2008 | 380 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2009 | 786 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2008 | 325 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2019 | 404 | 0.060 |
Why?
| | Acute Lung Injury | 1 | 2009 | 287 | 0.060 |
Why?
| | Bronchoscopy | 3 | 2012 | 223 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 92 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 385 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1809 | 0.060 |
Why?
| | Health Expenditures | 1 | 2006 | 189 | 0.060 |
Why?
| | Child Day Care Centers | 1 | 2005 | 36 | 0.060 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 549 | 0.060 |
Why?
| | Homeostasis | 1 | 2009 | 621 | 0.060 |
Why?
| | Biopsy | 1 | 2008 | 1129 | 0.060 |
Why?
| | Glycosylation | 1 | 2025 | 151 | 0.060 |
Why?
| | Infant | 5 | 2018 | 9465 | 0.060 |
Why?
| | Fats | 1 | 2024 | 17 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2008 | 435 | 0.060 |
Why?
| | Cost of Illness | 1 | 2006 | 308 | 0.050 |
Why?
| | Survival Rate | 1 | 2009 | 1972 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2024 | 44 | 0.050 |
Why?
| | Up-Regulation | 2 | 2020 | 843 | 0.050 |
Why?
| | Chemokine CCL26 | 2 | 2014 | 10 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 263 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 2 | 2015 | 93 | 0.050 |
Why?
| | Hormones | 1 | 2024 | 143 | 0.050 |
Why?
| | Nursing Homes | 1 | 2005 | 181 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 4030 | 0.050 |
Why?
| | Epigenomics | 1 | 2023 | 115 | 0.050 |
Why?
| | Recurrence | 2 | 2016 | 1060 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 21 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2531 | 0.050 |
Why?
| | Hand Strength | 1 | 2023 | 123 | 0.050 |
Why?
| | Americas | 1 | 2022 | 28 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2005 | 261 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 431 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 530 | 0.050 |
Why?
| | Biology | 1 | 2023 | 88 | 0.050 |
Why?
| | Latin America | 1 | 2022 | 93 | 0.050 |
Why?
| | Glycocholic Acid | 1 | 2021 | 6 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2021 | 10 | 0.050 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 21 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 76 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2836 | 0.050 |
Why?
| | Respiratory Hypersensitivity | 1 | 2021 | 69 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 411 | 0.040 |
Why?
| | Expectorants | 1 | 2021 | 24 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 11 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 622 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 184 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 971 | 0.040 |
Why?
| | International Cooperation | 2 | 2011 | 198 | 0.040 |
Why?
| | Canada | 1 | 2022 | 418 | 0.040 |
Why?
| | Dermatitis, Atopic | 1 | 2024 | 329 | 0.040 |
Why?
| | New York City | 1 | 2020 | 85 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 31 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 219 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 625 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 247 | 0.040 |
Why?
| | Altitude | 2 | 2016 | 488 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 279 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 171 | 0.040 |
Why?
| | Research | 1 | 2023 | 451 | 0.040 |
Why?
| | Stroke | 1 | 2008 | 1120 | 0.040 |
Why?
| | Trichloroethanes | 1 | 2018 | 1 | 0.040 |
Why?
| | Trichloroethylene | 1 | 2018 | 8 | 0.040 |
Why?
| | Patient Discharge | 1 | 2005 | 897 | 0.040 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2019 | 53 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 342 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1066 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 343 | 0.040 |
Why?
| | Groundwater | 1 | 2018 | 40 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1291 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 37 | 0.040 |
Why?
| | Indians, North American | 1 | 2024 | 643 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 275 | 0.040 |
Why?
| | Nose | 1 | 2018 | 67 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2426 | 0.040 |
Why?
| | Growth | 1 | 2018 | 60 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2018 | 92 | 0.040 |
Why?
| | Epithelium | 1 | 2019 | 313 | 0.040 |
Why?
| | Chlorobenzenes | 1 | 2017 | 9 | 0.040 |
Why?
| | Cyclohexenes | 1 | 2017 | 6 | 0.040 |
Why?
| | Toluene | 1 | 2017 | 13 | 0.030 |
Why?
| | Pentanes | 1 | 2017 | 11 | 0.030 |
Why?
| | Xylenes | 1 | 2017 | 9 | 0.030 |
Why?
| | Benzene | 1 | 2017 | 18 | 0.030 |
Why?
| | Terpenes | 1 | 2017 | 22 | 0.030 |
Why?
| | Oils | 1 | 2017 | 21 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 323 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 409 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 104 | 0.030 |
Why?
| | Communication | 1 | 2023 | 879 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2016 | 37 | 0.030 |
Why?
| | Biomass | 1 | 2017 | 118 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1431 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 447 | 0.030 |
Why?
| | Crop Production | 1 | 2016 | 1 | 0.030 |
Why?
| | Succinates | 1 | 2016 | 22 | 0.030 |
Why?
| | Southwestern United States | 1 | 2016 | 91 | 0.030 |
Why?
| | Plant Breeding | 1 | 2016 | 25 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 331 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 375 | 0.030 |
Why?
| | Glucosides | 1 | 2016 | 44 | 0.030 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2015 | 3 | 0.030 |
Why?
| | Receptors, Interleukin-17 | 1 | 2015 | 5 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1381 | 0.030 |
Why?
| | Algal Proteins | 1 | 2015 | 6 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 190 | 0.030 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 215 | 0.030 |
Why?
| | Hospital Costs | 1 | 2016 | 117 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 195 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1100 | 0.030 |
Why?
| | Photosystem I Protein Complex | 1 | 2014 | 2 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1670 | 0.030 |
Why?
| | Proton-Motive Force | 1 | 2014 | 6 | 0.030 |
Why?
| | Hydroxylation | 1 | 2015 | 39 | 0.030 |
Why?
| | Chlorophyll | 1 | 2014 | 14 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 131 | 0.030 |
Why?
| | Thylakoids | 1 | 2014 | 6 | 0.030 |
Why?
| | Carbon Cycle | 1 | 2014 | 18 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2017 | 347 | 0.030 |
Why?
| | Fever | 1 | 2016 | 306 | 0.030 |
Why?
| | Starch | 1 | 2014 | 22 | 0.030 |
Why?
| | Industry | 1 | 2015 | 68 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2016 | 290 | 0.030 |
Why?
| | Chemokine CXCL9 | 1 | 2014 | 27 | 0.030 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 17 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 585 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 117 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 119 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1329 | 0.030 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2014 | 65 | 0.030 |
Why?
| | Critical Illness | 1 | 2020 | 811 | 0.030 |
Why?
| | Exons | 1 | 2015 | 355 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 186 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 224 | 0.030 |
Why?
| | Fluorescence | 1 | 2014 | 160 | 0.030 |
Why?
| | Sepsis | 1 | 2020 | 617 | 0.030 |
Why?
| | Docosahexaenoic Acids | 1 | 2015 | 84 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2014 | 144 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 113 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 372 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Temperature | 1 | 2017 | 679 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 786 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4565 | 0.030 |
Why?
| | Risk | 1 | 2016 | 912 | 0.030 |
Why?
| | Acute Disease | 1 | 2016 | 1007 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2847 | 0.030 |
Why?
| | Lipocalins | 1 | 2013 | 36 | 0.030 |
Why?
| | Treatment Failure | 1 | 2014 | 356 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2013 | 68 | 0.030 |
Why?
| | Steel | 1 | 2012 | 6 | 0.030 |
Why?
| | Meteorological Concepts | 1 | 2012 | 6 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 469 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2012 | 26 | 0.020 |
Why?
| | Genome | 1 | 2015 | 300 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1943 | 0.020 |
Why?
| | Spatio-Temporal Analysis | 1 | 2012 | 34 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 976 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 657 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2057 | 0.020 |
Why?
| | Heart Failure | 1 | 2005 | 2236 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 816 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2011 | 60 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 886 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3457 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2031 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 806 | 0.020 |
Why?
| | Pain | 1 | 2016 | 756 | 0.020 |
Why?
| | Proteome | 1 | 2015 | 472 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 852 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 858 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 931 | 0.020 |
Why?
| | Seasons | 1 | 2012 | 547 | 0.020 |
Why?
| | Chemical Hazard Release | 1 | 2009 | 1 | 0.020 |
Why?
| | Railroads | 1 | 2009 | 5 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1035 | 0.020 |
Why?
| | Glutathione Reductase | 1 | 2009 | 25 | 0.020 |
Why?
| | South Carolina | 1 | 2009 | 38 | 0.020 |
Why?
| | Malondialdehyde | 1 | 2009 | 29 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 228 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2009 | 18 | 0.020 |
Why?
| | Glutathione Peroxidase | 1 | 2009 | 43 | 0.020 |
Why?
| | Voice Disorders | 1 | 2009 | 26 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 922 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2008 | 14 | 0.020 |
Why?
| | Cough | 1 | 2009 | 122 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 578 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5131 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3412 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2013 | 828 | 0.020 |
Why?
| | Office Visits | 1 | 2006 | 93 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 302 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2006 | 245 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2006 | 546 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1704 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2553 | 0.010 |
Why?
|
|
Holguin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|